Based on the timing of the acquisition, the Company, for comparability purposes, has disclosed the pro-forma earnings information for the six months ended June 30, 2012, as if the acquisition had occurred effective January 1, 2012. As such, the actual and pro-forma earnings information for the six months ended June 30, 2013 and June 30, 2012 was as follows:

	Six Months Ended June 30, 2013						Six Months Ended June 30, 2012
	Vystar		SleepHealth		Consolidated		Vystar		SleepHealth		Consolidated

Revenues, net	$	15,339	$	519,112	$	534,451	$	144,447	$	579,080	$	723,527

Cost of revenues		4,167		407,112		411,279		143,483		399,734		543,217
Gross profit (loss)		11,172		112,000		123,172		964		179,346		180,310

Operating expenses
Sales and marketing		135,331		-		135,331		214,344		355		214,699
General and administrative		881,814		226,617		1,108,431		759,182		203,388		962,570
Research and development		19,634		-		19,634		23,075		-		23,075
Total operating expenses		1,036,779		226,617		1,263,396		996,601		203,743		1,200,344

Loss from operations		(1,025,607)		(114,617)		(1,140,224)		(995,637)		(24,397)		(1,020,034)

Other income (expense)
Other income		(60)		2,500		2,440		5,250		-		5,250
Interest income		7		6,534		6,541		300		-		300
Interest expense		(311,079)		(8,054)		(319,133)		(279,430)		(8,463)		(287,893)

Net loss	$	(1,336,739)	$	(113,637)		(1,450,376)	$	(1,269,517)	$	(32,860)	$	(1,302,377)

Loss per Share	$	(0.05)	$	(0.01)		(0.06)	$	(0.07)	$	(0.00)	$	(0.07)

Basic and Diluted Weighted Average Number of Common Shares Outstanding						24,822,740						19,627,397